Vera Therapeutics Net Worth

Vera Therapeutics Net Worth Breakdown

  VERA
The net worth of Vera Therapeutics is the difference between its total assets and liabilities. Vera Therapeutics' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Vera Therapeutics' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Vera Therapeutics' net worth can be used as a measure of its financial health and stability which can help investors to decide if Vera Therapeutics is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Vera Therapeutics stock.

Vera Therapeutics Net Worth Analysis

Vera Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Vera Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Vera Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Vera Therapeutics' net worth analysis. One common approach is to calculate Vera Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Vera Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Vera Therapeutics' net worth. This approach calculates the present value of Vera Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Vera Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Vera Therapeutics' net worth. This involves comparing Vera Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Vera Therapeutics' net worth relative to its peers.
To determine if Vera Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Vera Therapeutics' net worth research are outlined below:
Vera Therapeutics had very high historical volatility over the last 90 days
The company reported the previous year's revenue of 1.86 M. Net Loss for the year was (95.99 M) with profit before overhead, payroll, taxes, and interest of 0.
Vera Therapeutics currently holds about 131.93 M in cash with (92.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.86.
Vera Therapeutics has a poor financial position based on the latest SEC disclosures
Over 95.0% of the company outstanding shares are owned by institutional investors
Vera Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Vera Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Vera Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
26th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Follow Vera Therapeutics' market capitalization trends

The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.06 B.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vera Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vera Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vera Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Carter Jason S 2 days ago
Acquisition by Carter Jason S of 108000 shares of Vera Therapeutics at 44.81 subject to Rule 16b-3
 
Fordyce Marshall over a month ago
Disposition of 600 shares by Fordyce Marshall of Vera Therapeutics at 41.6127 subject to Rule 16b-3
 
Fordyce Marshall over a month ago
Disposition of 3352 shares by Fordyce Marshall of Vera Therapeutics at 38.8312 subject to Rule 16b-3
 
Fordyce Marshall over two months ago
Disposition of 900 shares by Fordyce Marshall of Vera Therapeutics at 46.79 subject to Rule 16b-3
 
Seidenberg Beth C over two months ago
Disposition of 13823 shares by Seidenberg Beth C of Vera Therapeutics at 42.3058 subject to Rule 16b-3
 
Fordyce Marshall over two months ago
Disposition of 6351 shares by Fordyce Marshall of Vera Therapeutics at 37.7753 subject to Rule 16b-3
 
Fordyce Marshall over two months ago
Disposition of 700 shares by Fordyce Marshall of Vera Therapeutics at 37.5286 subject to Rule 16b-3
 
Fordyce Marshall over three months ago
Disposition of 14471 shares by Fordyce Marshall of Vera Therapeutics at .764 subject to Rule 16b-3
 
Fordyce Marshall over three months ago
Disposition of 15625 shares by Fordyce Marshall of Vera Therapeutics at 37.5633 subject to Rule 16b-3
 
Cheng Andrew over six months ago
Acquisition by Cheng Andrew of 14000 shares of Vera Therapeutics at 42.69 subject to Rule 16b-3
 
Grant Sean over six months ago
Disposition of 201 shares by Grant Sean of Vera Therapeutics at 38.231 subject to Rule 16b-3
 
Katabi Maha over six months ago
Disposition of 413450 shares by Katabi Maha of Vera Therapeutics at 40.51 subject to Rule 16b-3
Vera Therapeutics time-series forecasting models is one of many Vera Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Vera Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Vera Therapeutics Earnings per Share Projection vs Actual

Vera Therapeutics Corporate Management

Tad ThomasSr ManufacturingProfile
Lauren MBAChief OfficerProfile
Marshall MDPresident, FounderProfile
Jason CarterChief OfficerProfile
Julien JDSenior LegalProfile
Joanne CurleyChief OfficerProfile
Kerry MDSenior AffairsProfile
When determining whether Vera Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vera Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vera Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vera Therapeutics Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vera Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Vera Stock refer to our How to Trade Vera Stock guide.
You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vera Therapeutics. If investors know Vera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vera Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Vera Therapeutics is measured differently than its book value, which is the value of Vera that is recorded on the company's balance sheet. Investors also form their own opinion of Vera Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vera Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vera Therapeutics' market value can be influenced by many factors that don't directly affect Vera Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vera Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vera Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vera Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.